

IFa



ATTORNEY'S DOCKET NUMBER: 2003080-0144 (SK-1028-US)
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Veach *et al.* Examiner: Not yet assigned
Serial No.: 10/751,703 Art Unit: 1614
Filed: January 5, 2004
For: PYRIDOPYRIMIDINE KINASE INHIBITORS

Mail Stop: Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT UNDER 37 C.F.R. §§ 1.56, 1.97, & 1.98

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

- [X] An *original* Information Disclosure Statement; or
[] A *supplemental* Information Disclosure Statement.

Certificate of Mailing	
I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop: Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
<u>January 26 2005</u> Date	<u>[Signature]</u> Signature
<u>Lisa A. Walsh</u> Typed or Printed Name of person signing certificate	



ATTORNEY DOCKET NUMBER: 2003080-0144 (SK-1028-US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Veach *et al.* Examiner: Not yet assigned
Serial No.: 10/751,703 Art Unit: 1614
Filing Date: January 5, 2004
Title: PYRIDOPYRIMIDINE KINASE INHIBITORS

Mail Stop: Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Enclosed are the following documents:

1. Form PTO-1449 (5 pages);
2. Information Disclosure Statement (6 pages);
3. Cited Art (85); and
4. Return Postcard

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,

C. Hunter Baker, M.D., Ph.D.
Registration No. 46,533

Choate, Hall & Stewart
Exchange Place
53 State Street
Boston, MA 02109
(617) 248-5000
(617) 248-4000

Dated: Jan. 26, 2005

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

- ☒ Pursuant to 37 CFR § 1.97(b); no fee or certification is required:
 - ☐ Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
 - ☐ Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
 - ☒ Before the mailing of a first Office action on the merits; or
 - ☐ Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.
- ☐ Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:
 - ☐ Certifies that *either*:
 - ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
 - ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the

knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; or

☐ Includes herewith the fee set forth in § 1.17(p). Please charge Deposit Account No. 03-1721.

☐ Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *both*:

☐ Certifies that *either*:

☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; and

☐ Includes herewith the fee set forth in § 1.17(p).

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

☒ A copy of each cited reference not indicated with an asterisk is included;

☐ Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

☐ Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

☒ Does not contain non-English language citations;

☐ Does contain non-English language citations, for which an English language abstract is submitted.

[] Does contain non-English language citations which were cited on an International Search Report (a copy of which is enclosed herewith).

[] Includes one or more translations of a non-English citation.

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b) .

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,



C. Hunter Baker, M.D., Ph.D.

Reg. No. 46,533


CHOATE, HALL & STEWART
Exchange Place
53 State Street
Boston, Massachusetts 02109
(617) 248-5000
(617) 248-4000

Date: *Jan. 26, 2005*

3790213

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Applicant: Veach et al.,

Filing Date:
January 5, 2004

Group:
1614

U.S. PATENT DOCUMENTS

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
	6,242,452	Ogino et al.	June 5, 2001	514	258
	6,114,339	Gangjee	September 5, 2000	514	258
	5,977,163	Li et al.	November 2, 1999	514	449
	5,945,422	Doherty et al.	August 31, 1999	514	258
	5,733,914	Blankley et al.	March 31, 1998	514	258
	5,733,913	Blankley et al.	March 31, 1998	514	258
	5,620,981	Blankley et al.	April 15, 1997	514	258
	5,521,184	Zimmerman	May 28, 1996	514	252
	4,677,108	Kleinschroth et al.	June 30, 1987	514	258
	4,271,164	Blankley et al.	June 2, 1981	424	251
	4,252,946	Wood et al.	February 24, 1981	544	279
	4,113,859	Wood et al.	September 12, 1978	424	180
	3,639,401	Meyer et al.	February 1, 1972	260	256.4
	3,534,039	Davoll et al.	October 13, 1970	260	256.4

U.S. PATENT APPLICATIONS

Examiner's Initials:	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:
	2002/0137756	Chen et al.	September 26, 2002		
	2002/0055513	Arzeno et al.	May 9, 2002	514	258

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No
	EP 0 537 463	Europe	02 September 1992		
	WO 03/057165	International	17 July 2003		
	WO 02/18380	International	07 March 2002		
	WO 02/12238	International	14 February 2002		
	WO 01/44258	International	21 June 2001		
	WO 98/33798	International	06 August 1998		
	WO 96/34867	International	07 November 1996		

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 2003080-0144 (SK-1028-US)		In re Application No. 10/751,703	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant: Veach et al.,			
				Filing Date: January 5, 2004		Group: 1614	
OTHER DOCUMENTS							
Examiner's Initials		Citation (Including Author, Title, Date, Pertinent Pages, Etc.)					
		Allen, et al., "An Activating Mutation in the ATP Binding Site of the ABL Kinase Domain", <i>J. Biol. Chem.</i> 271 : 19585-19591, 1996.					
		Azam, et al., "Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL", <i>Cell</i> , 112 : 831-843, 2003.					
		Bai, et al., "Nucleophosmin-Anaplastic Lymphoma Kinase Associated with Anaplastic Large-Cell Lymphoma Activates the Phosphatidylinositol 3-Kinase/Akt Antiapoptotic Signaling Pathway", <i>Blood</i> , 96 : 4319-4327, 2000.					
		Barker, et al., "Characterization of pp60 ^{c-src} Tyrosine Kinase Activities Using a Continuous Assay: Autoactivation of the Enzyme Is An Intermolecular Autophosphorylation Process", <i>Biochemistry</i> , 34 : 14843-14851, 1995.					
		Beran, et al., "Selective Inhibition of Cell Proliferation and BCR-ABL Phosphorylation in Acute Lymphoblastic Leukemia Cells Expressing Mr 190,000 BCR-ABL Protein by a Tyrosine Kinase Inhibitor (CGP-57148)", <i>Clin. Cancer Res.</i> 4 : 1661-1672, 1998.					
		Berge, et al., "Pharmaceuticals Salts" <i>Journal of Pharmaceutical Sciences</i> , 66 : 1-19, 1977.					
		Branford, et al., "High Frequency of Point Mutations Clustered within the Adenosine Triphosphate-Binding Region of BCR/ABL in Patients with Chronic Myeloid Leukemia or Ph-Positive Acute Lymphoblastic Leukemia who Develop Imatinib (STI571) Resistance" <i>Blood</i> , 99 : 3472-3475, 2002.					
		Boschelli, et al., "Synthesis and Tyrosine Kinase Inhibitory Activity of a Series of 2-Amino-8H-Pyrido[2,3-d]pyrimidines: Identification of Potent, Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors", <i>J. Med. Chem.</i> 41 (22): 4365-4377, 1998.					
		Brunger, et al., "Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination", <i>Acta Crystallogr D. Biol. Crystallogr.</i> 54 (Pt. 5): 905-921, 1998.					
		Buchdunger, et al., "Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits in Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors", <i>J. Pharmacol. Exp. Ther.</i> 295 : 139-145, 2000.					
		Buchdunger, et al., "Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylaminopyrimidine Derivative" <i>Cancer Res.</i> , 56 : 100-104, 1996.					
		Corbin, et al., "Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571", <i>J. Biol. Chem.</i> 277 : 32214-32219, 2002.					
		Daly, et al., "Induction of Chronic Myelogenous Leukemia in Mice by the P210 ^{bcr/abl} Gene of the Philadelphia Chromosome", <i>Science</i> , 247 : 824-830, 1990.					
		Deininger, et al., "Direct Relation Between BCR-ABL Tyrosine Kinase Activity and Cyclin D2 Expression in Lymphoblasts", <i>Cancer Research</i> , 61 : 8005-8013, 2001.					
		Dorsey, et al., "The Pyrido[2,3-d]pyrimidine Derivative PD180970 Inhibits p210Bcr-Abl					

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 2003080-0144 (SK-1028-US)	In re Application No. 10/751,703
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant: Veach et al.,	
				Filing Date: January 5, 2004	Group: 1614
	Tyrosine Kinase and Induces Apoptosis of K562 Leukemic Cells”, <i>Cancer Res.</i> 60 : 3127-3131, 2000.				
	Druker, et al., “Effects of a Selective Inhibitor of the Abl Tyrosine Kinase on the Growth of Bcr-Abl Positive Cells”, <i>Nat. Med.</i> 2 : 561-566, 1996.				
	Druker, et al., “Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase In Chronic Myeloid Leukemia” <i>N. Engl. J. Med.</i> , 344 : 1031-1037, 2001.				
	Druker, et al., “STI571: Targeting BCR-ABL as Therapy for CML”, <i>Oncologist</i> , 6 : 233-238, 2001.				
	Druker, et al., “Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome”, <i>N. Engl. J. Med.</i> , 344 : 1038-1042, 2001.				
	Faderl, et al., “The Biology of Chronic Myeloid Leukemia”, <i>N. Engl. J. Med.</i> , 341 : 164-172, 1999.				
	Gorre, et al., “BCR-ABL Point Mutants Isolated from Patients with Imatinib Mesylate-Resistant Chronic Myeloid Leukemia Remain Sensitive to Inhibitors of the BCR-ABL Chaperone Heat Shock Protein 90”, <i>Blood</i> , 100 : 3041-3044, 2002.				
	Hantschel, et al., “A Myristoyl/Phosphotyrosine Switch Regulates c-Abl”, <i>Cell</i> , 112 : 845-857, 2003.				
	Hochhaus, et al., “Molecular and Chromosomal Mechanisms of Resistance to Imatinib (STI571) Therapy”, <i>Leukemia</i> , 16 : 2190-2196, 2002.				
	Hofmann, et al., “Ph+ Acute Lymphoblastic Leukemia Resistant to the Tyrosine Kinase Inhibitor STI571 Has a Unique BCR-ABL Gene Mutation” <i>Blood</i> , 99 : 1860-1862, 2002.				
	Hubbard, et al., “Crystal Structure of the Tyrosine Kinase Domain of the Human Insulin Receptor”, <i>Nature</i> , 372 : 746-754, 1994.				
	Jackson, et al., “N-Terminal Mutations Activate the Leukemogenic Potential of the Myristoylated Form of c-abl”, <i>EMBO. J.</i> , 8 : 449-456, 1989.				
	Kantarjian, et al., “Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia”, <i>N. Engl. J. Med.</i> , 346 : 645-652, 2002.				
	Klutchko, et al., “2-Substituted Aminopyrido[2,3-d]Pyrimidin-7 (8H)-Ones. Structure-Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity”, <i>J. Med. Chem.</i> , 41 (17): 3276-3292, 1998.				
	Kraker, et al., “Biochemical and Cellular Effects of c-Src Kinase-Selective Pyrido[2,3-d]Pyrimidine Tyrosine Kinase Inhibitors” <i>Biochem. Pharmacol.</i> 60 : 885-898, 2000.				
	La Rosee, et al., “Activity of the Bcr-Abl Kinase Inhibitor PD180970 Against Clinically Relevant Bcr-Abl Isoforms That Cause Resistance to Imatinib Mesylate (Gleevec, STI571)”, <i>Cancer Res.</i> , 62 : 7149-7153, 2002.				
	Le Coutre, et al., “In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells with an ABL Kinase Inhibitor”, <i>J. Natl Cancer Inst.</i> , 91 : 163-168, 1999.				

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 2003080-0144 (SK-1028-US)		In re Application No. 10/751,703	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant: Veach et al.,			
				Filing Date: January 5, 2004		Group: 1614	
	Lugo, et al., "Tyrosine Kinase Activity and Transformation Potency of <i>bcr-abl</i> Oncogene Products", <i>Science</i> , 247 : 1079-1082, 1990.						
	Manley, et al., "Molecular Interactions Between Gleevec TM and Mutant Forms of cAbl Kinase", <i>Proc. Am. Assoc. Cancer Res.</i> 4196: 2002.						
	Moasser, et al., "Inhibition of Src Kinases by a Selective Tyrosine Kinase Inhibitor Causes Mitotic Arrest", <i>Cancer Res.</i> 59 : 6145-6152, 1999.						
	Mohammadi, et al., "Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors", <i>Science</i> , 276 : 955-960, 1997.						
	Nagar, et al., "Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571)", <i>Cancer Res.</i> , 62 : 4236-4243, 2002.						
•	Nagar, et al., "Structural Basis for Autoinhibition of c-Abl Tyrosine Kinase", <i>Cell</i> , 112 : 859-871, 2003.						
•	Navaza, "AMoRe: An Automated Package for Molecular Replacement", <i>Acta Crystallogr A.</i> , 50 : 157-163, 1994.						
	Nowell, et al., "A Minute Chromosome in Human Chronic Granulocytic Leukemia", <i>Science</i> , 132 : 1497-1501, 1960.						
	Ottmann, et al., "A Phase 2 Study of Imatinib in Patients with Relapsed or Refractory Philadelphia <i>Blood</i> , 100 : 1965-1971, 2002.						
•	Otwinowski, et al., "Processing of X-Ray Diffraction Data Collected in Oscillation Mode", <i>Methods in Enzymology</i> , 276 : 307-326, 1997.						
	Parada, et al., "BCR-ABL and Interleukin 3 Promote Haematopoietic Cell Proliferation and Survival Through Modulation of Cyclin D2 and p27 ^{Kip1} Expression", <i>J. Biol. Chem.</i> 276 : 23572-23580, 2001.						
	Pear, et al., "Efficient and Rapid Induction of a Chronic Myelogenous Leukemia-Like Myeloproliferative Disease in Mice Receiving P210 <i>bcr/abl</i> -Transduced Bone Marrow", <i>Blood</i> , 92 : 3780-3792, 1998.						
	Plattner, et al., "c-Abl is Activated by Growth Factors and Src Family Kinases and Has a Role in the Cellular Response to PDGF", <i>Genes Dev.</i> 13 : 2400-2411, 1999.						
	Roche-Lestienne, et al., "Several Types of Mutations of the <i>Abl</i> Gene Can be Found in Chronic Myeloid Leukemia Patients Resistant to STI571, and They Can Pre-Exist to the Onset of Treatment", <i>Blood</i> , 100 : 1014-1018, 2002.						
	Roumiantsev, et al., "Clinical Resistance to the Kinase Inhibitor STI-571 in Chronic Myeloid Leukemia by Mutation of Tyr-253 in the Abl Kinase Domain P-loop", <i>Proc. Natl Acad. Sci. USA</i> , 99 : 10700-10705, 2002.						
	Rowley, et al., "A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia Identified by Quinacrine Fluorescence and Giemsa Staining", <i>Nature</i> , 243 : 290-293, 1973.						
	Sawyers, C., "Chronic Myeloid Leukemia", <i>N. Engl. J. Med.</i> , 340 : 1330-1340, 1999.						

Form PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2003080-0144 (SK-1028-US)	In re Application No. 10/751,703
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant: Veach et al.,	
		Filing Date: January 5, 2004	Group: 1614

	Sawyers, et al., "Imatinib Induces Hematologic and Cytogenetic Responses in Patients with Chronic Myelogenous Leukemia in Myeloid Blast Crisis: Results of a Phase II Study", <i>Blood</i> , 99 : 3530-3539, 2002.
	Schindler, et al., "Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase", <i>Science</i> , 289 : 1938-1942, 2000.
	Shah, et al., "Multiple BCR-ABL Kinase Domain Mutations Confer Polyclonal Resistance to the Tyrosine Kinase Inhibitor Imatinib (ST1571) in Chronic Phase and Blast Crisis Chronic Myeloid Leukemia", <i>Cancer Cell</i> , 2 : 117-125, 2002.
	Talpaz, et al., "Imatinib Induces Durable Hematologic and Cytogenetic Responses in Patients with Accelerated Phase Chronic Myeloid Leukemia: Results of a Phase 2 Study", <i>Blood</i> , 99 : 1928-1937, 2002.
	Trumpp-Kallmeyer, et al., "Development of a Binding Model to Protein Tyrosine Kinases for Substituted Pyrido[2,3-d]Pyrimidine Inhibitors", <i>J. Med. Chem.</i> 41 : 1752-1763, 1998.
	Van Etten, "Cycling, Stressed-Out and Nervous: Cellular Functions of c-Abl", <i>Trends Cell Biol.</i> , 9 : 179-186, 1999.
	Von Bubnoff, et al., "BCR-ABL Gene Mutations in Relation to Clinical Resistance of Philadelphia-Chromosome-Positive Leukaemia to ST1571: a Prospective Study", <i>Lancet</i> , 359 : 487-491, 2002.
	Warmuth, et al., "The Src Family Kinase Hck Interacts with Bcr-Abl by a Kinase-Independent Mechanism and Phosphorylates the Grb2-Binding Site of Bcr", <i>J. Biol. Chem.</i> 272 : 33260-33270, 1997.
	Wisniewski, et al., "Characterization of Potent Inhibitors of the Bcr-Abl and the c-Kit Receptor Tyrosine Kinases", <i>Cancer Res.</i> 62 : 4244-4255, 2002..
	Wolff, et al., "Establishment of a Murine Model for Therapy-Treated Chronic Myelogenous Leukemia Using the Tyrosine Kinase Inhibitor ST1571", <i>Blood</i> , 98 : 2808-2816, 2001.
	Yamaguchi, et al., "Structural Basis for Activation of Human Lymphocyte Kinase Lck Upon Tyrosine Phosphorylation", <i>Nature</i> , 384 : 484-489, 1996.
	Zheng, et al., "Crystal Structure of the Catalytic Subunit of cAMP-Dependent Protein Kinase Complexed with MgATP and Peptide Inhibitor", <i>Biochemistry</i> , 32 : 2154-2161, 1993.
	Zimmerman, et al., "Potent and Selective Inhibitors of the ABL-Kinase: Phenylamino-Pyrimidine (PAP) Derivatives" <i>Bioorg. Med. Chem. Lett.</i> , 7 : 187-192, 1997.
	International Search Report issued for corresponding PCT application PCT/US2004/000116.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.